Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.47 |
| ▸ | LPL | P06858 | 7/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177947 | 0.83 | LIPG (0.61) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL31720865 | 0.82 | LIPG (0.65) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL19794357 | 0.81 | LIPG (0.46) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL19933638 | 0.80 | LIPG (0.46) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL19794354 | 0.79 | DGAT1 (0.53) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL29626026 | 0.78 | LIPG (0.55) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL20696474 | 0.77 | LIPG (0.43) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL23487532 | 0.77 | LIPG (0.54) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL22947717 | 0.77 | LIPG (0.50) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL21397945 | 0.77 | LIPG (0.45) | LIPGLPLPDGFRBKDRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220209141-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| WO-2020212296-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220209141-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | LIPG 3289/4885LPL 3220/4885PDGFRB 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.